<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="55493">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02102932</url>
  </required_header>
  <id_info>
    <org_study_id>1276.23</org_study_id>
    <nct_id>NCT02102932</nct_id>
  </id_info>
  <brief_title>Bioavailability of Empagliflozin/Metformin Fixed Dose Combination(FDC) in Healthy Chinese Volunteers</brief_title>
  <official_title>Relative Bioavailability of Empagliflozin (12.5 or 5 mg)/Metformin (850 mg or 500 mg) Fixed Dose Combination Tablets Compared to Single Tablets Administered Together to Healthy Chinese Male and Female Volunteers in an Open-label, Randomised, Single-dose, Two-way Crossover Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the trial is to assess the relative bioavailability of fixed dose combination
      tablets of  Empagliflozin and metformin compared to the administration of single tablets
      (Empagliflozin  and metformin ) in Chinese subjects. The availability of a fixed dose
      combination tablet is expected to significantly enhance patient's compliance with
      antidiabetic treatment, in particular with concern to the frequent polypharmacy in diabetic
      patients.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>AUC0-infinity (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)</measure>
    <time_frame>up to 8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax (maximum measured concentration of the analyte in plasma)</measure>
    <time_frame>up to 8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point)</measure>
    <time_frame>up to 8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>12.5 mg empagliflozin/850 mg metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>24 subjects (12 male and 12 female) will be assigned to 2 treatment sequences. cross-over design was adopted to ensure each patient would take fixed dose combination tablets of 12.5 mg empagliflozin/850 mg metformin and single 10 mg empagliflozin, 2.5 mg empagliflozin, 850 mg metformin tablets single dose in randomized order</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5 mg empagliflozin/850 mg metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>24 subjects (12 male and 12 female) will be assigned to 2 treatment sequences. cross-over design was adopted to ensure each patient would take fixed dose combination tablets of 5 mg empagliflozin/850 mg metformin and single Empagliflozin(5mg) and metformin (850mg) tablets single dose in randomized order</description>
  </arm_group>
  <arm_group>
    <arm_group_label>12.5 mg empagliflozin/500 mg metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>24 subjects (12 male and 12 female) will be assigned to 2 treatment sequences. cross-over design was adopted to ensure each patient would take fixed dose combination tablets of 12.5 mg empagliflozin/500 mg metformin and single 10 mg empagliflozin, 2.5 mg empagliflozin, 500 mg metformin tablets single dose in randomized order</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5 mg empagliflozin/500 mg metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>24 subjects (12 male and 12 female) will be assigned to 2 treatment sequences. cross-over design was adopted to ensure each patient would take fixed dose combination tablets of 5 mg empagliflozin/500 mg metformin and single Empagliflozin(5mg) and metformin (500mg) tablets single dose in randomized order</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5 mg empagliflozin/850 mg metformin FDC</intervention_name>
    <description>5 mg empagliflozin/850 mg metformin FDC</description>
    <arm_group_label>5 mg empagliflozin/850 mg metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>12.5 mg empagliflozin</intervention_name>
    <description>10 mg empagliflozin tablet and 2.5 mg empagliflozin tablet</description>
    <arm_group_label>12.5 mg empagliflozin/500 mg metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>12.5 mg empagliflozin</intervention_name>
    <description>10mg empagliflozin tablet and 2.5 mg empagliflozin tablet</description>
    <arm_group_label>12.5 mg empagliflozin/850 mg metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>850 mg metformin</intervention_name>
    <description>850mg metformin tablet</description>
    <arm_group_label>12.5 mg empagliflozin/850 mg metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5 mg empagliflozin</intervention_name>
    <description>5 mg empagliflozin</description>
    <arm_group_label>5 mg empagliflozin/850 mg metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5 mg empagliflozin</intervention_name>
    <description>5 mg empagliflozin</description>
    <arm_group_label>5 mg empagliflozin/500 mg metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>850 mg metformin</intervention_name>
    <description>850 mg metformin</description>
    <arm_group_label>5 mg empagliflozin/850 mg metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>12.5 mg empagliflozin/850 mg metformin FDC</intervention_name>
    <description>12.5 mg empagliflozin/850 mg metformin FDC</description>
    <arm_group_label>12.5 mg empagliflozin/850 mg metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>12.5 mg empagliflozin/500 mg metformin FDC</intervention_name>
    <description>12.5 mg empagliflozin/500 mg metformin FDC</description>
    <arm_group_label>12.5 mg empagliflozin/500 mg metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5 mg empagliflozin/500 mg metformin FDC</intervention_name>
    <description>5 mg empagliflozin/500 mg metformin FDC</description>
    <arm_group_label>5 mg empagliflozin/500 mg metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>500 mg metformin</intervention_name>
    <description>500 mg metformin</description>
    <arm_group_label>12.5 mg empagliflozin/500 mg metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>500 mg metformin</intervention_name>
    <description>500 mg metformin</description>
    <arm_group_label>5 mg empagliflozin/500 mg metformin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        Healthy male and female subjects

        Exclusion criteria:

        Any relevant deviation from healthy conditions
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Boehringer Ingelheim Call Center</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>1276.23.86002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 20, 2014</lastchanged_date>
  <firstreceived_date>March 31, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
